Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream for scalp psoriasis: patients report better satisfaction and quality of life

NCT ID NCT05811234

Symptom relief Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study followed 291 adults with mild-to-moderate scalp psoriasis who were prescribed a cream containing calcipotriene and betamethasone (Wynzora®). Researchers measured how satisfied patients were with the treatment, its effect on quality of life, and how well it worked in real-world settings over 12 weeks. The goal was to see if the cream improves daily life and symptom control beyond what is seen in controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Calcipotriene/Betamethasone dipropionate cream (Wynzora®)
What this could lead to
If successful, this could show that the cream improves treatment satisfaction and quality of life for people with scalp psoriasis in everyday use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It also only looks at short-term outcomes (12 weeks) and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

291 people

The number who actually took part.

Started

Jun 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male and female participants with mild-to-moderate plaque psoriasis of the scalp will be observed in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult (greater than or equal to \[\>=\] 18 years) male or female participants with mild-to-moderate plaque psoriasis of the scalp (defined as scalp-PGA score of 2 or 3 at baseline) with or without involvement of the trunk and limbs, and who may or may not have been previously treated (treatment-naive participants) with other anti-psoriatic therapies. 2. Participants who have been prescribed CAL/BDP PAD cream (Wynzora®) treatment to manage plaque psoriasis of the scalp according to SmPC in routine clinical practice. 3. Willingness and ability to participate in the study; participants must give their written consent to participate. Exclusion Criteria: 1. Participants with severe plaque psoriasis, per physician global assessment. 2. Participants with erythrodermic, exfoliative or pustular psoriasis. 3. Participants previously treated with systemic drugs for psoriasis (conventional or biologic) within the last 12 weeks prior to inclusion. 4. Concomitant systemic treatment with anti-psoriatic drugs. 5. Concomitant treatment of any type for plaque psoriasis of the scalp. 6. Hypersensitivity to the active substances or to any of the excipients of CAL/BDP PAD cream (Wynzora®). 7. Participants with known disorders of calcium metabolism. 8. Participants with viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers, and wounds. 9. Pregnant or breastfeeding women, except when the potential benefit justifies the potential risk. 10. Participants unable to comply with the requirements of the study or who in the opinion of the study physician should not participate in the study. 11. Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • DE01

    Mannheim, Germany

  • DE02

    Potsdam, Germany

  • DE03

    Mönchengladbach, Germany

  • DE04

    Pforzheim, Germany

  • DE05

    Mölln, Germany

  • DE06

    Cologne, Germany

  • DE07

    Augsburg, Germany

  • DE08

    Freising, Germany

  • DE10

    Mainz, Germany

  • DE11

    Remscheid, Germany

  • DE12

    Ahaus, Germany

  • ES01

    Zaragoza, Spain

  • ES02

    Barcelona, Spain

  • ES03

    Granollers, Spain

  • ES04

    Alcorcón, Spain

  • ES05

    Bilbao, Spain

  • ES06

    Barcelona, Spain

  • ES07

    Lleida, Spain

  • ES08

    Pontevedra, Spain

  • ES09

    Barcelona, Spain

  • ES10

    Badalona, Spain

  • ES11

    Seville, Spain

  • ES12

    Salamanca, Spain

  • ES13

    Seville, Spain

  • UK01

    London, United Kingdom

  • UK02

    Chertsey, United Kingdom

  • UK03

    Crewe, United Kingdom

  • UK04

    Salisbury, United Kingdom

  • UK05

    Saint Neots, United Kingdom

  • UK06

    Chipping Norton, United Kingdom

  • UK07

    Exeter, United Kingdom

  • UK08

    Cockermouth, United Kingdom

  • UK10

    Blackburn, United Kingdom

  • UK11

    Leicester, United Kingdom

  • UK12

    Wellingborough, United Kingdom

  • UK14

    Glasgow, United Kingdom

  • UK15

    Kirkcaldy, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.